To investigate the mechanisms by which ATP1B1 expression affects outcome in CN-AML, we first performed a genome-wide differential analysis after again subdividing the primary cohort of CN-AML patients based on the median ATP1B1 expression. The gene discussed is ATP1B1; the disease is cyclic hematopoiesis.